Axonics. has been granted a patent for a trial neurostimulation system featuring a lead extension with a regression stopper. This design prevents lead regression through incisions, ensuring electrical connection stability and reducing infection risk during neurostimulation trials. The patent details methods for assembling and utilizing these devices. GlobalData’s report on Axonics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Axonics, Neuromodulation implants was a key innovation area identified from patents. Axonics's grant share as of June 2024 was 53%. Grant share is based on the ratio of number of grants to total number of patents.
Neurostimulation lead extension with regression prevention features
The patent US12042662B2 describes a lead extension designed for use in neurostimulation therapies, particularly during trial periods. The lead extension features a distal connector that can be electrically coupled to a fully implanted neurostimulation lead and a proximal connector intended for connection to an external pulse generator. A key component of this design is an extension cable that links the two connectors, incorporating a regression stopper positioned between them. This stopper is engineered to prevent the lead extension from retracting into the patient's body through a second incision, ensuring stability during the procedure. The regression stopper is designed to pass through a tunneling tool or cannula along with the proximal connector, facilitating ease of use during implantation.
The claims further detail the characteristics of the regression stopper, which can be cylindrical, rigid, semi-rigid, or malleable, and may feature a flat surface that interfaces with the patient's skin or a gauze pad to inhibit regression. The lead extension is specifically configured for trial nerve stimulation, allowing for the delivery of stimulation from an external pulse generator to the implanted lead. The overall length of the lead extension is specified to be between 30 and 40 inches, with a segment between the regression stopper and the distal connector measuring 10 to 20 inches. The method of using this lead extension involves implanting a neurostimulation lead, tunneling between incision sites, and ensuring secure connections while preventing lead regression during the trial period or explantation.
To know more about GlobalData’s detailed insights on Axonics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
